Sort
82,697 grants matching “vaccine development”
Retrovirus Models of Lymphocyte Transformation/Disease
$1,980,571Michael D Lairmore · Ohio State University · P01 · FY2007 · CA
Mechanisms and Duration of Immunity to SARS-CoV-2
$1,980,075Scott Dexter Boyd · Stanford University · U54 · FY2022 · CA
Centers for AIDS Research (CFAR)
$1,979,638Kent J. Weinhold · Duke University · P30 · FY2019 · AI
Molecular Determinants of Tissue-resident Memory T cell Fate in Acute and Chronic Infection
$1,978,465Ananda W Goldrath · University Of California, San Diego · P01 · FY2019 · AI
Innate Immune Antivirals for Biodefense
$1,978,174Michael J Gale · University Of Washington · R01 · FY2016 · AI
Comprehensive Sickle Cell Center
$1,977,867Winfred C Wang · St. Jude Children'S Research Hospital · U54 · FY2006 · HL
Consultation and Collaboration
$1,977,655Barry Graubard · Division Of Cancer Epidemiology And Genetics · ZIA · FY2014 · CA
MBRS-SCORE PROGRAM AT UPR, MEDICAL SCIENCES CAMPUS
$1,977,529University Of Puerto Rico Med Sciences · S06 · FY2001 · GM
Case Clinical Trials Unit
$1,977,369Michael Marcel Lederman · Case Western Reserve University · UM1 · FY2017 · AI
Adjuvant development within the context of a vaccine to protect against B. pertussis
$1,977,192Lisa Morici · Tulane University Of Louisiana · N01 · FY2021 · AI
Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit
$1,977,185Jeffrey Lennox · Emory University · UM1 · FY2015 · AI
HIV VACCINE TRIAL CLINICAL UNIT
$1,976,524Harvard University (Medical School) · U01 · FY2001 · AI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
$1,975,833Shan Lu · Univ Of Massachusetts Med Sch Worcester · P01 · FY2011 · AI
EXPANSION OF NIH CHIMPANZEE HOLDING FAC
$1,975,176University Of Louisiana At Lafayette · C06 · FY2002 · RR
CHIMPANZEE HOLDNG FAC EXPANSION: HEALTH &WELL BEING FOR CHIMPANZEE NERVOUS SYST
$1,975,176University Of Louisiana At Lafayette · C06 · FY2002 · RR
Cocktail of Neutralizing MAbs for Smallpox Prevention
$1,975,114Jeffrey L Nordstrom · Macrogenics, Inc. · U01 · FY2008 · AI
Shaping Antiviral Immunity by the Inflammatory, Regulatory and Tissue Environment
$1,974,689E. John Wherry · University Of Pennsylvania · U19 · FY2010 · AI
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
$1,974,550Linda-Gail Bekker · University Of Cape Town · UM1 · FY2023 · AI
Host-Tumor Cell Interactions in Myeloma:
$1,974,474Dana-Farber Cancer Institute · P01 · FY2004 · CA
Host-tumor cell interaction in myeloma: therapeutic applications
$1,974,463Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2012 · CA
NIDA Clinical Trials Network: Greater New York Node
$1,974,434John P Rotrosen · New York University School Of Medicine · UG1 · FY2019 · DA
HIV Vaccine Design and Development Team
$1,974,283Progenics Pharmaceuticals, Inc. · R01 · FY2000 · AI
Vaccination against mucosal HIV clade C transmission
$1,974,218Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · P01 · FY2009 · AI
Cancer Immune Monitoring and Analysis Center
$1,973,873Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · U24 · FY2023 · CA
CD40L adjuvanted clade C DNA and MVA HIV vaccines
$1,973,313Rama Rao Amara · Emory University · U19 · FY2015 · AI